بررسی اثرات آنتی هیستامین دیمن هیدرینات بر آنزیم‌های تست عملکرد کبدی و بافت کبد در موش‌های صحرایی نر

نوع مقاله: مقاله پژوهشی

نویسندگان

1 گروه زیست شناسی، واحد قم، دانشگاه آزاد اسلامی، قم، ایران

2 پژوهشگاه رویان، پژوهشکده زیست شناسی و فناوری سلول های بنیادی جهاد دانشگاهی، مرکز تحقیقات علوم سلولی، گروه سلول های بنیادی و زیست شناسی تکوینی، تهران، ایران

چکیده

دیمن هیدرینات به عنوان یک داروی ضد تهوع و آنتی رفلاکس معدی در موارد تهوع ناشی از مسافرت مورد استفاده می‌باشد. این دارو به راحتی از راه خوراکی جذب می‌گردد. متابولیسم دیمن هیدرینات کبدی است و از کلیه‌ها به صورت متابولیت دفع می‌گردد. در این تحقیق به بررسی اثرات داروی آنتی­هیستامین دیمن هیدرینات بر بافت کبد و آنزیم‌های کبدی و تأثیرات بالقوه سوء تجویز بیش از حد این دارو پرداخته‌ایم. از 40 سر موش صحرایی نر نژاد ویستار در محدوده وزنی 20 ± 250 گرم استفاده شد. رت‌ها در چهار گروه ده تایی تقسیم شدند. یک گروه تیمار با دوزهای مختلف 250، 500 و 750  میلی­گرم بر کیلوگرم نسبت به وزن بدن از دارو به صورت خوراکی روزانه به مدت 28 روز داده شد. که در پایان دوره، حیوانات را با استفاده از استنشاق اتر کشته و از خون جهت تست­های آنزیمی و کبد جهت انجام آزمایشات پاتولوژی نمونه­برداری بعمل آمد. مقایسه سطح آنزیم­های AST، ALT و ALP در گروه‌های تیمار 5/2، 5 و 5/7 در مقایسه با گروه کنترل افزایش نشان داد (05/0p<). بررسی‌های بافت شناسی کبد گروه‌های تیمار، تخریب سینوزوئیدها، از بین رفتن مجاری صفراوی، نامرتب قرارگیری سلول‌ها کنار هم و عدم وجود سلول‌های کوپفر را نمایان کرد که مشخص کننده اثر تخریبی دیمن هیدرینات بر بافت کبد است. دیمن هیدرینات همانند سایر داروها علاوه بر اثرات مثبت می‌تواند اثرات نامطلوبی نیز داشته باشد. یکی از بافت‌های تحت آسیب کبد است، لذا بایستی هنگام تجویز عوارض ناخواسته دارو نیز در نظر گرفته شود.

کلیدواژه‌ها


عنوان مقاله [English]

The Study of Dimenhydrinate Antihistamine`s Effects on Liver`s Tissue and Enzymes in Male Rats

نویسندگان [English]

  • O. Naemi 1
  • K. Roshanayi 1
  • F. Jamalloo 1
  • M. Ahmadifar 2
1 Department of Biology, Qom Branch, Islamic Azad University, Qom, Iran
2 Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
چکیده [English]

In this study, we checked the distractive effects of dimenhydramine antihistamine on liver`s tissue and enzymes thereinafter excessive prescription. Dimenhydramine is a drug with anti-gastric reflux and anti-nausea effects usually used in trip for sensitive persons. This drug absorbed easily from oral usage and during 24 h excreted from kidneys and it has hepatic metabolism. We used 40 male Wistar adult rats whit 250+20 weighting that grouped into four groups. The control group was without treatment and the other fed with 2.5, 5, 7.5 mg/kg of dienhydramine doses daily within 28 d. After the examination procedure, rats became unconscious with ether, blood sampling and liver`s biopsy were done and sent to the laboratory for more study. Comparing the enzyme levels of ALT, AST, and ALP in the treatment and control groups, there was a rise in the enzyme levels as a result of liver damage caused by taking dimenhydramine antihistamine. Observing the microscopic slides of the liver tissue of the treatment group, it suggests sinusoid destruction, the loss of bile ducts, irregular placement of adjacent cells and the absence of Kupffer cells, which in turn confirms the negative effect of this drug on liver tissue. Like other medications, dienhydramine can exert adversary effects as well as positive effects. Since one of the tissues which are susceptible to this effect is liver, we must bear in mind when it comes to prescribing this medication.

کلیدواژه‌ها [English]

  • liver
  • Dimenhydramine
  • Antihistamine
  • Rat

1. Abernathy C.O., Zimmerman H.J., Ishak K.G., Utili R., Gillespie J., 2003. Drug - induced cholestasis in the perfused rat liver and its reversal by tauroursodeoxycholate: an ultrastructural study. Proceedings of the Society for Experimental Biology and Medicine, 199(1): 54-8. 

2. Androli T., Carpenter C., Griggs R., Benjamin I., 2007. Diseases of the Liver and Biliary System. in: Cecil'sEssentials of Medicine. 7th ed. USA: WB Saunders Company, 23.

3. Arteel G., Marsano L., Mendez C., Bentley F., McClain C.J., 2003. Advances in alcoholic liver disease. Best Practice & Research Clinical Gastroenterology, 17: 625–47.

4. Azer S.A., Stacey N.H., 2001. Current concept of hepatic uptake, intracellular transport and biliary secretion of bile acids: physiological basis and pathophysiological changes in cholestatic liver dysfunction. Journal of Gastroenterology Hepatology, 11(4): 396-407.

5. Bloomgarden Z.T., 2005:  Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and famotidine liver disease. Diabetes Care, 28: 1518-1523.

6. Becker U., Deis A., Sorensen T.I., 2009. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology, 23: 1025–9.

7. Bellentani S., Tiribelli C., Saccoccio G., 2011. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology, 20: 1442–9.

8. Bellentani S., Saccoccio G., Costa G., 2008. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut, 41: 845–50.

9. Bouchier I.A.D., Hislop W.S., Prescott R.J., 2007. A prospective study of alcoholic liver disease and mortality. Journal of  Hepatology, 16: 290–7.

10. Bell H., Jahnsen J., Kittang E., Raknerud N., Sandvik L., 2004. Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit. Scandinavian Journal of Gastroenterology, 39: 858– 63.

11. Brunt E.M., Tiniakos D.G., 2010. Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 16: 5286-5296.

12. Charde M., Kurane P., Dhabale P., 2015. Development of Stability Indicating Assay Method for Estimation of Ibuprofen and Famotidine in Combined Dosage Form in Tablet. International Journal of Advances in Pharmaceutical Analysis, 5(4): 85-92

 

13. Corrao G., Arico S., Zambon A., 2010. Is alcohol a risk factor for liver cirrhosis in HBsAg and anti-HCV negative subjects? Collaborative Groups for the Study of Liver Diseases in Italy. Journal   of Hepatology, 27: 470–6.

14. Glass J.R., Sproule B.A., Herrmann N., Busto U.E., 2008. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a ran- domized, placebo-controlled trial. Journal of Clinical Psychopharmacology, 28: 182–188.

15. Kuitunen M., Kukkonen K., Juntunene-Backman K., Korpela R., Poussa T., Tuure T, 2009. Probiotics prevent associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. Journal of Allergy and Clinical Immunology, 123: 335-41.

16. Kerr J.B., Maddocks S., Sharpe R.M., 2003. SGPT and SGOT have independent, synergistic and stage-dependent effects upon Liver in the rat Liver. Journal of Cell and Tissue Research, 268:179–189.

17. Karanth J., Jeevaratnam K. 2010. Effect of carnitine supplementation on mitochondrial enzymes in liver and skeletal muscle of rat after dietary lipid manipulation and physical activity. Indian Journal of Experimental Biology, 48: 503-510.

18. Luper S.A. 2005. Review of plants used in the treatment of liver disease. Alternatvie Medicine Review, 3: 40-2.

19. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., 2001. Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 50: 2002-1850

20. Neuberger J., Schulz K.H., Day C., 2002. Transplantation for alcoholic liver disease. Journal of Hepatology, 36: 130–7.

21. Pageaux G.P., Bismuth M., Perney P., 2003. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? Journal of Hepatology, 38: 629–34.

22. Palabiyik I.M., Onur F., 2007. Simultaneous Spectrophotometric  Determination of Pseudoepedrine  Sulphate and Loratadine in a Pharmaceutical Preparation Using Chemometric Techniques. Journal of Faculty of Pharmacy of Ankara University, 36(3): 171-182.

23. Poullis A.P., Shetty A.K., Risley P.D., Collinson P.O., Mendall M.A., 2003. Effect of the CD14 promoter polymorphism on liver function tests and its association with alcohol and obesity. European Journal of Gastroenterology & Hepatology, 15: 1317–22.

24. Rouault T.A., 2003. Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis? Alcohol, 30: 103–6.

25. Stickel F., Osterreicher C.H., 2006. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol, 41: 209– 24.

26. Sherlac S., 2001. Discases of the liver and bilary system 8 edition black Well scientific. Oxford, P: 1-12

27. Safdar K., Schiff E.R., Alcohol and hepatitis C., Semin Liver Dis 2004; 24: 305– 15. 35) Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2014; 24: 217–32.

28. Stewart S., Jones D., Day C.P., 2001. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends in Molecular Medicine, 7: 408–13.

29. Sorensen T.I., Orholm M., Bentsen K.D., Hoybye G., Eghoje K., Christoffersen P., 2012.Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet, 2: 241–4.

30. Tome S., Lucey M.R., 2004. Review article: current management of alcoholic liver disease. Alimentary Pharmacology & Therapeutics, 19: 707–14.

31. Teli M.R., Day C.P., Burt A.D., 2011. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet, 346: 1562–3.

32. Zintzaras E., Stefanidis I., Santos M., Vidal F., 2006. Do alcohol-metabolizing enzyme gene polymorphism increase the risk of alcoholism and alcoholic liver disease? Hepatology, 43: 352–61.